Neonatal encephalopathy is a syndrome of disturbed neurological function during the first days of life. Newborns may show abnormal consciousness, poor muscle tone, weak reflexes, seizures, difficulties with breathing or problems feeding. Hypoxic-ischemic injury, caused by insufficient oxygen and blood flow to the brain, is one important cause, but infection, inflammation, metabolic disorders, stroke, genetic disease and other conditions can produce similar signs. For that reason, the term “hypoxic-ischemic encephalopathy,” or HIE, should not automatically be applied to every infant with neonatal neurological dysfunction.

The urgency of assessing severity increased after therapeutic hypothermia became standard care for selected infants with moderate to severe HIE. Cooling the newborn to approximately 33–34 degrees Celsius for about 72 hours can reduce secondary brain injury when it is initiated within the first six hours after birth. Yet the criteria used to determine eligibility are based largely on early clinical observations, blood-gas measurements, neurological examinations and evidence of a difficult birth. These indicators are valuable, but they are snapshots taken during a rapidly changing process. A newborn who appears severely impaired immediately after delivery may improve quickly, while another with initially subtle signs may deteriorate as cellular injury evolves.

Clinical grading systems are therefore central to neonatal care, but they have limits. Common examinations assess consciousness, spontaneous activity, posture, muscle tone, primitive reflexes, autonomic function and seizures. These domains help clinicians distinguish degrees of encephalopathy, but they are influenced by gestational age, medication, sedation, pain, respiratory support, temperature and the infant’s general medical condition. Premature infants may display neurological signs that differ from those of term newborns, and an examination performed shortly after resuscitation may not reflect the infant’s eventual neurological state.

The article’s central message is that severity should be understood as a multidimensional and time-dependent measurement rather than a single label. The brain injury process can include an initial period of energy failure, a temporary phase of partial recovery and a later wave of secondary damage involving excitotoxicity, oxidative stress, inflammation, mitochondrial dysfunction and cell death. Because these processes unfold over hours and days, severity cannot always be captured accurately by one examination at one moment. Repeated assessments may reveal a trajectory, showing whether neurological function is recovering, remaining stable or worsening.

Electroencephalography and amplitude-integrated electroencephalography offer one way to observe this trajectory. These techniques record the brain’s electrical activity and can identify abnormal background patterns, reduced variability and seizures that may not produce visible movements. Electrographic seizures are particularly important because newborns can have “electroclinical dissociation,” in which abnormal electrical activity continues even after outward signs disappear. A persistently severely abnormal background pattern may indicate substantial cerebral dysfunction, whereas normalization over time can provide evidence of neurological recovery. However, interpretation requires expertise, and electrical patterns can be affected by anticonvulsant medication and other treatments.

Brain imaging adds another layer of information. Magnetic resonance imaging, especially diffusion-weighted imaging and magnetic resonance spectroscopy, can reveal patterns of injury in the basal ganglia, thalamus, watershed regions and white matter. Diffusion abnormalities may emerge early as injured cells lose the ability to regulate water movement, while later scans can show the established distribution and extent of damage. Magnetic resonance spectroscopy can provide metabolic information, including changes in lactate and other chemical signals associated with impaired energy production. Imaging is not a perfect crystal ball, however: timing matters, findings can evolve, and the relationship between a scan and an individual child’s developmental outcome is probabilistic rather than absolute.

Biomarkers from blood, urine or cerebrospinal fluid are also being investigated as tools for refining severity assessment. Molecules such as neuron-specific enolase, S100 calcium-binding protein B, glial fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 may rise when neurons or glial cells are damaged. Other candidates reflect inflammation, oxidative stress, mitochondrial injury or disruption of the blood-brain barrier. The attraction of biomarkers is clear: a rapid laboratory test could complement bedside examination and potentially identify hidden injury. But biological markers can be influenced by organ failure, infection, prematurity and the timing of sample collection. Most remain research tools rather than stand-alone tests for making high-stakes decisions.

Arnáez also highlights a fundamental problem in neonatal research: severity is often defined differently from one study to another. One investigation may use the initial neurological examination, another may classify infants according to cooling eligibility, and a third may rely on MRI, seizure burden or developmental outcomes at 18 or 24 months. These definitions are related, but they are not interchangeable. If studies enroll different populations under the same label of “moderate encephalopathy,” comparisons become difficult and the apparent effectiveness of treatments may be distorted. More consistent severity frameworks could improve clinical trials by allowing researchers to determine which infants benefit from an intervention, at what stage and under which biological conditions.

A more precise approach would combine several forms of evidence: perinatal history, early and repeated neurological examinations, continuous brain monitoring, neuroimaging, laboratory biomarkers and carefully selected developmental outcomes. Such a model would not replace clinical judgment or reduce an infant to a numerical score. Instead, it would recognize that neonatal encephalopathy is a dynamic syndrome with different causes, injury patterns and recovery pathways. The most useful measure of severity may ultimately be a profile that describes the infant’s current neurological state, the likely mechanism of injury and the direction of change over time.

This shift could also improve communication with families. A label such as “mild encephalopathy” may sound reassuring even though some infants with initially mild signs later develop seizures, developmental delays or learning difficulties. Conversely, an early severe presentation does not make an individual outcome inevitable. Families need explanations that acknowledge uncertainty while describing the evidence emerging from examinations, monitoring and imaging. Prognosis should be updated as new information becomes available, rather than being fixed by a single early assessment.

The broader significance extends beyond neonatal intensive care. Better measurement could support trials of treatments that complement cooling, including strategies aimed at reducing inflammation, stabilizing mitochondrial function, controlling seizures or promoting repair. It could also help distinguish infants with genuine hypoxic-ischemic injury from those whose encephalopathy has another cause, ensuring that therapies are tested in biologically appropriate groups. The challenge is to develop tools that are reliable across hospitals, practical during the narrow window when treatment can help and validated against meaningful long-term outcomes.

Neonatal encephalopathy is therefore moving from a diagnostic label toward a measurable process. The categories of mild, moderate and severe remain useful for urgent clinical decisions, but they are only the starting point. A combination of serial examinations, brain activity monitoring, imaging and molecular evidence may provide a more accurate account of what is happening inside the newborn brain. By looking beyond definitions, clinicians and researchers may be better equipped to identify injury early, tailor treatment and understand why infants with apparently similar beginnings can follow very different developmental paths.

Subject of Research: Measuring severity, prognosis and biological progression in neonatal encephalopathy.

Article Title: Beyond definitions: measuring severity in neonatal encephalopathy

Article References:

Arnáez, J. Beyond definitions: measuring severity in neonatal encephalopathy. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05378-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-026-05378-6

Keywords: neonatal encephalopathy, hypoxic-ischemic encephalopathy, neonatal brain injury, therapeutic hypothermia, neuroimaging, electroencephalography, biomarkers, neonatal neurology, prognosis, newborn health

Neonatal encephalopathy, characterized clinically by disturbed neurological function in the earliest days of life, often results from hypoxic-ischemic insults, infections, or metabolic disturbances. The heterogeneity of these insults complicates prognosis and management, making the need for reliable predictive markers exceedingly critical. Traditional assessments have relied heavily on clinical examinations and biochemical markers, which, while valuable, fall short in prognostic precision. Brain imaging techniques, including magnetic resonance imaging (MRI) and advanced neuroimaging protocols like diffusion tensor imaging (DTI), have emerged as pivotal tools in delineating the extent and nature of brain injury with remarkable accuracy.

This study delves into the application of sophisticated MRI sequences to map cerebral injury patterns at a microstructural level. By visualizing the integrity of white matter tracts and identifying regions of ischemic damage, researchers can now infer the severity of injury with a granularity previously unattainable. Notably, diffusion-weighted imaging (DWI), which captures the movement of water molecules along neuronal fibers, reveals areas of cytotoxic edema indicative of acute ischemic injury, enabling early and sensitive detection of brain lesions.

Furthermore, the authors emphasize the prognostic power of combining structural imaging with functional assessments such as magnetic resonance spectroscopy (MRS). MRS quantifies metabolite concentrations like N-acetylaspartate (NAA), lactate, and choline, metabolic fingerprints that correlate strongly with neuronal health and injury. In neonates with encephalopathy, deviations from normative metabolite ratios have shown robust associations with adverse neurodevelopmental outcomes, establishing MRS as a biomarker for functional integrity.

Crucially, the research underscores that timing of imaging is paramount. Imaging within the first week post-insult captures the acute phase of brain injury wherein interventions might be optimized. Imaging beyond this window, while useful for chronic injury assessment, may miss the therapeutic window wherein neuroplasticity and repair are most dynamic. This temporal sensitivity of brain imaging enhances its utility not just as a diagnostic tool but as a guide for clinical decision-making.

The team also incorporated machine learning algorithms to interpret complex imaging data sets, heralding a new era of precision medicine in neonatology. These models synthesize multiple imaging parameters, from lesion location and extent to metabolite levels, producing individualized risk profiles that outperform traditional prognostic indices. Such predictive modeling offers hope for personalized interventions, ensuring that infants at highest risk receive timely, targeted therapies.

Importantly, the implications of this research extend beyond mere prediction. Early identification of infants likely to develop neurodevelopmental disabilities enables proactive rehabilitation strategies. For instance, infants identified at risk for cerebral palsy or cognitive impairments through imaging can be enrolled in early intervention programs, capitalizing on neuroplasticity to mitigate long-term deficits and improve quality of life.

The study also candidly discusses the challenges inherent in translating advanced imaging techniques into routine clinical practice. Limitations include the need for sedation in some infants, the availability of high-field MRI scanners in neonatal units, and the requirement for specialized expertise in image analysis. However, these barriers are increasingly surmountable with technology proliferation and interdisciplinary collaboration between radiologists, neurologists, and neonatologists.

This pioneering work also opens avenues for future research focused on refining imaging biomarkers and integrating them with genomics and electrophysiology. Combining multimodal data streams could yield a composite biomarker with unprecedented predictive accuracy, enabling clinicians to decode the complex neurobiological substrates underlying encephalopathy-related injury.

Additionally, the authors advocate for longitudinal studies that track imaging findings against developmental milestones through infancy and early childhood. Such longitudinal correlations will cement the role of brain imaging as the cornerstone of prognostic paradigms and therapeutic tailoring in neonatal encephalopathy.

In summary, the integrative neuroimaging strategies presented by Anarna and colleagues represent a watershed moment in neonatal brain injury research. By illuminating the pathways from acute injury to chronic impairment, these imaging modalities furnish a roadmap for early identification and intervention, holding promise to transform outcomes for vulnerable neonates worldwide.

As this research continues to evolve, it stands to empower clinicians with precision tools to not only foresee neurodevelopmental challenges but also to strategically combat them. The integration of advanced imaging into clinical protocols underscores the potential of medical imaging as a game-changing asset in pediatric neurological care.

With ongoing technological advancements, including portable MRI units and enhanced image-processing software, the standard of care for neonatal encephalopathy could soon incorporate routine brain imaging as a cornerstone of bedside evaluation. Such integration would democratize access to predictive diagnostics, particularly in resource-limited settings where early intervention remains critical yet often delayed.

This paradigm shift also raises important ethical considerations regarding prognostic disclosure and decision-making in the neonatal intensive care unit. Clinicians will need to navigate these complexities with sensitivity, ensuring that imaging-derived predictions are contextualized within holistic care plans involving families.

Ultimately, the compelling evidence presented in this seminal paper charts a promising course toward the goal of reducing the global burden of neurodevelopmental disabilities stemming from neonatal encephalopathy. Early and accurate prediction via brain imaging portends a future where tailored interventions can markedly enhance the developmental trajectories of the most vulnerable infants.

Subject of Research: The use of brain imaging techniques to predict neurodevelopmental outcomes in neonates with encephalopathy.

Article Title: Brain imaging as a predictor of neurodevelopmental outcomes in neonatal encephalopathy.

Article References:
Anarna, K., Gano, D. & Selvanathan, T. Brain imaging as a predictor of neurodevelopmental outcomes in neonatal encephalopathy. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04696-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04696-5